Lung cancer (Amsterdam, Netherlands) · 2025
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma.
СтатьяКлинический случайПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ruan Zhaohui, Zeng Liang, Zhang Jin, Qin Haoyue, Huang Zhe, Yan Huan, Zhang Gao, Zhang Yongchang
Аннотация
OBJECTIVES: Leptomeningeal metastasis (LM) is a serious complication of advanced non-small-cell lung cancer (NSCLC). Intrathecal administration of nivolumab or interleukin-2 (IL-2) has demonstrated efficacy in this setting. Preclinical and limited clinical evidence suggest that combining IL-2 with anti-PD1 therapy may synergistically enhance anti-tumor immunity. However, clinical data on the efficacy and safety of intrathecal co-administration of nivolumab and IL-2 are lacking.
MATERIALS AND METHODS: We describe a case of NSCLC with LM, refractory to multiple EGFR tyrosine kinase inhibitors and previous intrathecal therapies, treated with intrathecal nivolumab and IL-2. Single-cell RNA sequencing (scRNA-seq) was performed on cerebrospinal fluid (CSF) samples collected before and after treatment.
RESULTS: This is the first reported case of intrathecal nivolumab plus IL-2 in NSCLC with LM resistant to standard systemic and intrathecal therapies. The patient experienced marked clinical improvement, including substantial remission of intracranial metastases, neurological symptom relief, and a reduction in tumor marker levels, without notable treatment-related adverse events. scRNA-seq analysis of CSF revealed a post-treatment decrease in malignant cell populations and a concomitant increase in immune effector cells, particularly CD8+ T cells and NK cells. Malignant cells exhibited upregulated antigen presentation and apoptosis. Cell-cell interaction analysis indicated enhanced NK cell-mediated cytotoxicity via FASL-FAS signaling and reduced immunosuppressive interactions between regulatory CD4+ T cells and effector memory CD8+ T cells.
CONCLUSIONS: This case report provides preliminary evidence supporting the feasibility, safety, and potential efficacy of intrathecal nivolumab and IL-2 in treating NSCLC-associated LM. These findings warrant further investigation in prospective clinical studies.
MATERIALS AND METHODS: We describe a case of NSCLC with LM, refractory to multiple EGFR tyrosine kinase inhibitors and previous intrathecal therapies, treated with intrathecal nivolumab and IL-2. Single-cell RNA sequencing (scRNA-seq) was performed on cerebrospinal fluid (CSF) samples collected before and after treatment.
RESULTS: This is the first reported case of intrathecal nivolumab plus IL-2 in NSCLC with LM resistant to standard systemic and intrathecal therapies. The patient experienced marked clinical improvement, including substantial remission of intracranial metastases, neurological symptom relief, and a reduction in tumor marker levels, without notable treatment-related adverse events. scRNA-seq analysis of CSF revealed a post-treatment decrease in malignant cell populations and a concomitant increase in immune effector cells, particularly CD8+ T cells and NK cells. Malignant cells exhibited upregulated antigen presentation and apoptosis. Cell-cell interaction analysis indicated enhanced NK cell-mediated cytotoxicity via FASL-FAS signaling and reduced immunosuppressive interactions between regulatory CD4+ T cells and effector memory CD8+ T cells.
CONCLUSIONS: This case report provides preliminary evidence supporting the feasibility, safety, and potential efficacy of intrathecal nivolumab and IL-2 in treating NSCLC-associated LM. These findings warrant further investigation in prospective clinical studies.